Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma: Recurrence Pathway and Prognostic Factors

Pérez-Saborido, B.; Galanes, Santos Jiménez de los; Meneu-Diaz, J.C.; Romero, Carlos Jiménez; Elola-Olaso, A. Moreno; Suárez, Y. Fundora; Valencia, V. Barra; Moreno‐González, E.

doi:10.1016/j.transproceed.2007.06.059

Cited by 47 publications

(48 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In fact, Yao et al [62] in California require that patients with an initial AFP > 1000 ng/mL have AFP decreased to < 500 ng/mL after loco regional therapy, before undergoing LT. Similarly, in Yamashiki et al [43] 2004 93 United States Prospective 100 ng/mL Drop-out from list Shetty et al [42] 2004 109 United States Retrospective 300 ng/mL Recurrence, death Todo et al [54] 2007 653 Japan Retrospective 200 ng/mL Recurrence 1000 ng/mL Parfitt et al [61] 2007 75 Canada Retrospective 1000 ng/mL Recurrence Pérez-Saborido et al [44] 2007 95 Spain Retrospective 200 ng/mL Recurrence Onaca et al [10] 2007 902 United States Retrospective 200 ng/mL Recurrence Adler et al [86] 2008 226 Belgium Retrospective 100 ng/mL Recurrence Zou et al [45] 2008 303 China Retrospective 1000 ng/mL Fatal recurrence Ioannou et al [50] 2008 5028 United States Retrospective 455 ng/mL Death Xu et al [46] 2009 97 China Retrospective 400 ng/mL Recurrence Toso et al [49] 2009 6478 Canada Retrospective 400 ng/mL Death Lao et al [55] 2009 124 United States Prospective 1000 ng/mL Recurrence Xiao et al [87] 2009 224 China Retrospective 800 ng/mL Death McHugh et al [47] 2010 101 United States Retrospective 100 ng/mL Recurrence, death Levi et al [88] 2010 244 United States Retrospective 100 ng/mL Recurrence Merani et al [66] 2011 6817 United States Retrospective 400 ng/mL Death Lai et al [89] 2011 153 Italy Retrospective 210 ng/mL Recurrence Mailey et al [48] 2011 2253 United States Retrospective 400 ng/mL Death Muscari et al [28] 2012 122 France Retrospective 500 ng/mL Recurrence, death Ciccarelli et al [65] 2012 137 Belgium Retrospective 400 ng/mL Recurrence Wong et al [59] 2013 211 United States Retrospective 400 ng/mL Recurrence Harimoto et al [90] 2013 167 Japan Retrospective 300 ng/mL Recurrence Abdel-Wahab et al [68] 2013 170 Egypt Retrospective 200 ng/mL Recurrence, death Grąt et al [67] 2014 121 Poland Retrospective 100 ng/mL Recurrence Hameed et al [30] 2014 211 United States Retrospective 1000 ng/mL Microvascular invasion Lee et al [91] 2014 69 South Korea Retrospective 200 ng/mL Recurrence Grąt et al [...…”

Section: Evolution Of Afp Over Time: a Critical Markermentioning

confidence: 99%

Contribution of alpha-fetoprotein in liver transplantation for hepatocellular carcinoma

Charrière¹,

Maulat²,

Suc³

et al. 2016

WJH

View full text Add to dashboard Cite

Alpha-fetoprotein (AFP) is the main tumor biomarker available for the management of hepatocellular carcinoma (HCC). Although it is neither a good screening test nor an accurate diagnostic tool for HCC, it seems to be a possible prognostic marker. However, its contribution in liver transplantation for HCC has not been fully determined, although its use to predict recurrence after liver transplantation has been underlined by international societies. In an era of organ shortages, it could also have a key role in the selection of patients eligible for liver transplantation. Yet unanswered questions remain. First, the cut-off value of serum AFP above which liver transplantation should not be performed is still a subject of debate. We show that a concentration of 1000 ng/mL could be an exclusion criterion, whereas values of < 15 ng/mL indicate patients with an excellent prognosis whatever the size and number of tumors. Monitoring the dynamics of AFP could also prove useful. However, evidence is lacking regarding the values that should be used. Today, the real input of AFP seems to be its integration into new criteria to select patients eligible for a liver transplantation. These recent tools have associated AFP values with morphological criteria, thus refining pre-existing criteria, such as Milan, University of California, San Francisco, or "up-to-seven". We provide a review of the different criteria submitted within the past years. Finally, AFP can be used to monitor recurrence after transplantation, although there is little evidence to support this claim. Future challenges will be to draft new international guidelines to implement the use of AFP as a selection tool, and to determine a clear cut-off value above which liver transplantation should not be performed.

show abstract

Section: Evolution Of Afp Over Time: a Critical Markermentioning

confidence: 99%

Contribution of alpha-fetoprotein in liver transplantation for hepatocellular carcinoma

Charrière¹,

Maulat²,

Suc³

et al. 2016

WJH

View full text Add to dashboard Cite

show abstract

“…It has been reported that well-differentiated HCCs are associated with a longer recurrence-free survival after liver transplantation or hepatic resection than moderately and poorly differentiated HCCs [1][2][3][4][5]. For this reason, some surgeons suggest that the surgical plan should be modified depending on the histopathological differentiation, as well as other factors, by securing a larger free tumour margin or choosing other therapies, such as interventional ablative therapies, over liver transplantation in poorly differentiated HCCs [6,7].…”

Section: Introductionmentioning

confidence: 99%

Prediction of the histopathological grade of hepatocellular carcinoma using qualitative diffusion-weighted, dynamic, and hepatobiliary phase MRI

Park

Jeon

et al. 2012

Eur Radiol

View full text Add to dashboard Cite

show abstract

“…However, HCC recurs after liver transplantation in approximately 20%-30% of patients, and recurrence is difficult to treat and is the rate-limiting factor for long-term survival (3)(4)(5). For prediction of HCC recurrence and selection of appropriate candidates for liver transplantation, the Milan criteria, which consider size and number of tumors, have performed well (6), and some other pathologic factors also have been shown to be significant prognostic factors for posttransplantation recurrence (7,8). However, exact assessment of the Milan criteria and pathologic factors is not possible before liver transplantation, and thus, use of other laboratory tests or radiologic factors for selecting candidates has been attempted (8,9).…”

mentioning

confidence: 99%

Prediction of Posttransplantation Recurrence of Hepatocellular Carcinoma Using Metabolic and Volumetric Indices of ¹⁸F-FDG PET/CT

et al. 2016

View full text Add to dashboard Cite

18 F-FDG PET is an effective method of predicting recurrence of hepatocellular carcinoma (HCC) after liver transplantation. We compared recently introduced metabolic and volumetric 18 F-FDG PET/ CT indices with the current clinicopathologic predictors for ability to predict recurrence. Methods: In total, 110 HCC patients who underwent 18 F-FDG PET and liver transplantation were enrolled. On PET, SUVs and tumor-to-background ratios (TBRs) were measured as metabolic activity indices. Various metabolic tumor volumes and uptake-volume products (UVP) were also measured as volumetric indices. The ability of these indices and other clinicopathologic factors to predict recurrence was compared. Results: All metabolic and volumetric indices were significant for recurrence prediction on receiver-operating-characteristic curve analyses (P , 0.001). On univariate survival analyses, all PET indices-as well as tumor size, tumor number, the Milan criteria, tumor grade, vascular invasion, and T-stage-were significant factors. However, on multivariate analyses, tumor size, tumor grade, maximum TBR, and UVP calculated by inferior vena cava activity were significant factors (P 5 0.004, 0.014, 0.009, and 0.021, respectively). When the Milan criteria and PET factors were included in the multivariate analysis, the Milan criteria (P 5 0.029), maximum TBR (P , 0.001), and UVP (P 5 0.016) were significant. Conclusion: Volumetric and metabolic activity indices of 18 F-FDG PET are effective predictors of posttransplantation HCC recurrence. In addition to clinicopathologic factors, these indices need to be considered in the selection of candidates for liver transplantation.

show abstract

Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma: Recurrence Pathway and Prognostic Factors

Cited by 47 publications

References 13 publications

Contribution of alpha-fetoprotein in liver transplantation for hepatocellular carcinoma

Contribution of alpha-fetoprotein in liver transplantation for hepatocellular carcinoma

Prediction of the histopathological grade of hepatocellular carcinoma using qualitative diffusion-weighted, dynamic, and hepatobiliary phase MRI

Prediction of Posttransplantation Recurrence of Hepatocellular Carcinoma Using Metabolic and Volumetric Indices of ¹⁸F-FDG PET/CT

Contact Info

Product

Resources

About

Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma: Recurrence Pathway and Prognostic Factors

Cited by 47 publications

References 13 publications

Contribution of alpha-fetoprotein in liver transplantation for hepatocellular carcinoma

Contribution of alpha-fetoprotein in liver transplantation for hepatocellular carcinoma

Prediction of the histopathological grade of hepatocellular carcinoma using qualitative diffusion-weighted, dynamic, and hepatobiliary phase MRI

Prediction of Posttransplantation Recurrence of Hepatocellular Carcinoma Using Metabolic and Volumetric Indices of 18F-FDG PET/CT

Contact Info

Product

Resources

About

Prediction of Posttransplantation Recurrence of Hepatocellular Carcinoma Using Metabolic and Volumetric Indices of ¹⁸F-FDG PET/CT